Just in case current investor's didn't know.
Thank you for your continued interest in receiving our free stock alerts.
If you Are Uninterested in Receiving Free Stock Alerts, Please Unsubscribe Here
New Alert for Wed. 1/25/17
Blake Insomnia Therapeutics Inc. (BKIT)
Blake Insomnia Therapeutics (BKIT) has quickly begun to hit the radar especially in the OTC and it doesn't take long to see why (just pull up any chart)
After hitting highs of $1.60 last week, it would appear that not only has BKIT consolidated but Tuesday's (1-24) market activity could signal another bullish reversal in the works. This also comes on the heels of its most recent announcement about the company's drive to complete Phase II clinical testing of its patent-pending ZLX-1 compound.
Will You Be The One "Sleeping" On This Alert?
BKIT is focused on improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, ZleepaxTM.
Since the ZLX-1 patent application covers multiple active ingredient combinations, Phase II clinical testing will determine which combination and dosage will deliver the most potent effect. Of course after having secured proper funding for Phase II, BKIT would then target Phase III, the final step required to receive FDA approval...so we could be presented with BKIT on the cusp of something big.
But it may not be just the timing of this, that could have the attention of biotech's elite. ZleepaxTM is the first sleep aid with beta blockers as the major active agent. First generation beta blockers inhibited natural melatonin secretion and had a negative impact on sleep. Recent publications have shown that certain third-generation beta blockers actually improve quality of sleep for patients with mild hypertension.
Somewhere between 50 and 70 million Americans suffer from insomnia. Of these, close to 9 million take prescription pharmaceuticals to help them overcome the issue. More than 75% of these 9 million individuals, however, are dissatisfied with the drugs they are taking. The number one problem? A side effect called residual daytime sedation.
Additional issues, voiced by the FDA on approval of a variety of the currently approved standard of care therapies in the space, include sleep walking, hallucinations, violent outbursts and nocturnal binge eating. There’s a $3.6 billion market opportunity for a company that can come to market with a sleeping aid pharmaceutical that doesn’t have these side effects associated with it.
Where traditional hypnotics “force” people to sleep by depressing the central nervous system,BKIT's ZleepaxTM (ZLX-1) acts by diminishing the physical symptoms of stress that keep people awake at night.
BKIT states that according to patients, the No. 1 problem with traditional sleeping pills is residual daytime sedation. The potential for tolerance build-up and addiction are also major perceived disadvantages. Based on beta blockers, ZleepaxTM dramatically reduces these and many other unwanted side effects. This means that, in dramatic contrast to existing hypnotics, ZleepaxTM should be able to give many patients a better night’s sleep with fewer of the side effects they do not want
This Is Not Just About Sleep...It's About Productivity!
Sleep deprivation is a global issue, a recent report suggests that improving sleep habits and duration can have big implications, not only for an individual’s health and well-being but also for the global economy. Research has shown that simple changes to sleep duration can make a big difference.
For example, if Americans who sleep less than six hours a night increase their nightly sleep to between six and seven hours a night, this could add $226.4 billion to the U.S. economy.
Japan loses as much as $138 billion and 604,000 working days a year and the United Kingdom loses $50 billion and 207,000 working days a year. Even Germany, known for its efficiency and high levels of productivity, loses as much as $60 billion and 209,000 working days a year.
Meanwhile, Canada’s losses, despite being smaller, are still significant: as much as $21.4 billion and 78,000 working days a year...so where do you think the potential is for something like what BKIT has at its disposal.
The Bottom Line
Question: Is there a need? ... Did you see the numbers above?...Question #2: Is there a growing desire for a REAL solution? ...We saw it mentioned previously, "More than 75% of these 9 million individuals who take prescription pharmaceuticals are dissatisfied with the drugs they are taking."
On top of this, the attention has been mounting around BKIT in very recent weeks and Tuesday (1-24) marked the first day in 3 days since consolidating that BKIT has managed to see a green close. We've been on a hot streak for "right place, right time" situations. Could BKIT be the next on the list? Stay tuned, do your DD, and if you choose, be ready to go at the opening bell Wednesday morning (1-25).
Want Instant Updates on Our Alerts?
From Your Cell Phone Text “PENNYHUB” to 82257
